BACKGROUND: C-reactive protein is a predictor of adverse cardiovascular outcomes. The effect of antihypertensive therapy on C-reactive protein levels is largely unknown. METHOD: We undertook a cross-sectional study of CRP levels among participants with primary hypertension on single-agent anti-hypertensive therapy in the community-based biracial Genetic Epidemiology Network of Arteriopathy cohort. Linear regression models were used to assess the association of anti-hypertensive medication class with log-transformed C-reactive protein after adjustment for age, gender, ethnicity, body mass index, smoking, diabetes, HMG-Co-A reductase inhibitor use, achieved blood pressure control (<140/90 mmHg), serum creatinine and urine albumin-to-creatinine ratios. RESULTS: There were 662 participants in the cohort taking single-agent therapy for hypertension. Median C-reactive protein levels differed across participants: 0.40 mg/dL for those on diuretics, 0.34 mg/dL on calcium channel blockers, 0.25 mg/dL on beta blockers and 0.27 mg/dL on renin-angiotensin-aldosterone system inhibitors (p<0.001). With multivariable adjustment, the group on renin-angiotensin-aldosterone system inhibitors had a 20% lower mean CRP on average than the group on diuretics (p=0.044), differences between other medication classes were not apparent. Heart rate had a strong association with C-reactive protein (p < 0.001). CONCLUSIONS: Antihypertensive medication class may influence inflammation, particularly in patients on RAAS inhibitors.
BACKGROUND:C-reactive protein is a predictor of adverse cardiovascular outcomes. The effect of antihypertensive therapy on C-reactive protein levels is largely unknown. METHOD: We undertook a cross-sectional study of CRP levels among participants with primary hypertension on single-agent anti-hypertensive therapy in the community-based biracial Genetic Epidemiology Network of Arteriopathy cohort. Linear regression models were used to assess the association of anti-hypertensive medication class with log-transformed C-reactive protein after adjustment for age, gender, ethnicity, body mass index, smoking, diabetes, HMG-Co-A reductase inhibitor use, achieved blood pressure control (<140/90 mmHg), serum creatinine and urine albumin-to-creatinine ratios. RESULTS: There were 662 participants in the cohort taking single-agent therapy for hypertension. Median C-reactive protein levels differed across participants: 0.40 mg/dL for those on diuretics, 0.34 mg/dL on calcium channel blockers, 0.25 mg/dL on beta blockers and 0.27 mg/dL on renin-angiotensin-aldosterone system inhibitors (p<0.001). With multivariable adjustment, the group on renin-angiotensin-aldosterone system inhibitors had a 20% lower mean CRP on average than the group on diuretics (p=0.044), differences between other medication classes were not apparent. Heart rate had a strong association with C-reactive protein (p < 0.001). CONCLUSIONS: Antihypertensive medication class may influence inflammation, particularly in patients on RAAS inhibitors.
Authors: Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder Journal: Am J Med Date: 2003-07 Impact factor: 4.965
Authors: Jacques Amar; Jean-Bernard Ruidavets; Jean-Claude Peyrieux; Jean-Michel Mallion; Jean Ferrières; Michel E Safar; Bernard Chamontin Journal: Hypertension Date: 2005-06-13 Impact factor: 10.190
Authors: J S Pankow; A R Folsom; M Cushman; I B Borecki; P N Hopkins; J H Eckfeldt; R P Tracy Journal: Atherosclerosis Date: 2001-02-15 Impact factor: 5.162
Authors: Iftikhar J Kullo; James B Seward; Kent R Bailey; Lawrence F Bielak; Brandon R Grossardt; Patrick F Sheedy; Patricia A Peyser; Stephen T Turner Journal: Am J Hypertens Date: 2005-08 Impact factor: 2.689
Authors: Michael B Saddekni; Kenneth G Saag; Tanja Dudenbostel; Suzanne Oparil; David A Calhoun; Sebastian E Sattui; Daniel I Feig; Paul Muntner; David T Redden; Phillip J Foster; Elizabeth J Rahn; Stephanie R Biggers; Peng Li; Angelo L Gaffo Journal: Contemp Clin Trials Date: 2016-08-30 Impact factor: 2.226